{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-060513","form_type":"8-K","ticker":"DERM","cik":"0001867066","company_name":"Journey Medical Corp","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.990458+00:00","generated_at":"2026-06-02T02:46:57.472442+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Journey Medical Q1 rev $13M (+7% YoY); DFD-29 PDUFA Nov 4, 2024","bullets":["Net loss of $10.4M ($0.53 loss per share) vs $10.1M loss ($0.57 loss per share) in Q1 2023.","Non-GAAP Adjusted EBITDA turned positive at $11K ($0.001 per share) vs negative $5.3M prior year.","R&D expenses rose to $7.9M from $2.0M due to $4M FDA filing fee and $3M DRL milestone for DFD-29.","SG&A cut 37% to $8.4M; Qbrexza and Accutane each grew >20% YoY.","FDA accepted DFD-29 NDA for rosacea; PDUFA target action date November 4, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-060513","json":"https://secwatch.observer/filing/0001104659-24-060513.json","markdown":"https://secwatch.observer/filing/0001104659-24-060513.md","text":"https://secwatch.observer/filing/0001104659-24-060513.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867066/000110465924060513/0001104659-24-060513-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867066/000110465924060513/tm2414271d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:46:57.472442+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"210ca7991aac1997fb6600b060d3adc1cef62a2d","claim":"Journey Medical Corp reported first quarter ended March 31, 2024 results: revenue Total net product revenues were $13.0 million, net income Net loss was $10.4 million, EPS $(0.53) per share basic and diluted.","evidence_excerpt":"New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Total revenues for the first quarter ended March 31, 2024 were $13.0 million, a 7% increase from the $12.2 million reported in the first quarter of 2023 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867066/000110465924060513/0001104659-24-060513-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"Total net product revenues were $13.0 million"},{"label":"Net income","value":"Net loss was $10.4 million"},{"label":"EPS","value":"$(0.53) per share basic and diluted"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}